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ABSTRACT

Generalized linear models with Poisson error were applied to investigate
HIV/AIDS relative survival. Relative excess risk of death within 3 years after
HIV/AIDS diagnosis

was significantly higher for non-Hispanic blacks,

American Indians and Hispanics compared with non-Hispanic Whites. Excess
hazard of death was also higher among male injection drug users compared
with men who have sex with men (MSM). The relative excess hazard of old
HIV/AIDS patients was significantly higher compared with younger patients
(e.g., 60+ age group versus 19-29 year age group). When CD4 increased, the
relative excess hazard decreased; while with the increase of HIV viral load, the
relative excess hazard decreased. Our population-based results showed that
viral load was a determinant risk factor of disease progression after HIV
infection; basically the mean residual life has similar trend to relative survival.
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HIV/AIDS RELATIV ESURVIVAL ANALYSIS

BY

XINJIAN ZHANG

Thesis submitted as Partial Fulfillment of Requirements for the Degree of
Master of Science
in the College of Arts and Sciences
Georgia State University

2007

Copyright by
XINJIAN ZHANG
2007

HIV/AIDS RELATIVE SURVIVAL ANALYSIS

BY

XINJIAN ZHANG

Major Professor:
Committee:

Gengsheng (Jeff) Qin and
Ruiguang (Rick) Song
Xu Zhang
Yu-sheng Hsu

Electronic Version Approved:

Office of Graduate Studies
College of Arts and Sciences
Georgia State University
August 2007

iv

ACHKNOWLEDGEMENTS

I would like to express my sincere gratitude to the following persons for their
suggestion and assistance in the preparation of this thesis. Dr. Gengsheng (Jeff) Qin
served as my thesis advisor, gave me invaluable guidance and constant encouragement.
Without his direction and supervision, this thesis would not have been possible. Dr.
Ruiguang Song, as my thesis field director, spent countless hours in shaping the direction
of this thesis, offering me concrete suggestions in data manipulation and analysis. Many
thanks to Dr. Yu-sheng Hsu for providing critical advices.

I am deeply grateful to Dr. Kathleen McDavid Harrison for her advices and expertise
in HIV/AIDS epidemiology and surveillance. I also would like to thank the HIV Incidence
and Case Surveillance Branch at Centers for Diseases Control and Prevention (CDC) for
giving me the opportunity to access and analyze the HIV/AIDS reporting system (HARS)
data. They paved the way for me to get this thesis done.

Finally, I would like to thank my family and my friends who gave me constant
support and encouragement through the whole process.

v

TABLE OF CONTENTS

ACHKNOWLEDGEMENTS

iv

LIST OF TABLES

vii

LIST OF FIGURES

viii

CHAPTER
1

2

INTRODUCTION

1

History of HIV Infection

1

Epidemiology

2

Clinical Manifestation

3

Biology

5

Laboratory Diagnosis

6

Treatment and Prevention

7

Statistical Advance and Challenge in HIV/AIDS Modeling

9

HIV/AIDS relative survival and mean residual life analysis

10

METHODS

11

Data sources

11

Models and Estimation Approaches of Relative
Survival and Mean Residual Life

13

Variable Selection and Model Checking

16

vi
3

Data Analysis and Results

16

Variable selection and survival curve analysis

17

Relative survival from AIDS diagnosis to death

18

Relative survival from HIV infection diagnosis to death

19

Relative excess hazard ratio

20

AIDS free survival proportion from HIV to AIDS diagnosis

21

Model comparison and model checking

22

4

Discussion

22

5

Conclusions

28

REFERENCES

29

APPENDICES

52

A

ABBREVIATIONS

52

B

SAS AND SPLUS CODES

53

vii
LIST OF TABLES

Table 1 Relative survival after AIDS diagnosis from 1996 to 2003,
by 50 US States
34

Table 2 Relative survival after diagnosis from 1996 to 2003,
by 25 US States
36

Tables 3 Relative excess hazard rate of death within 3 years among
patients with HIV or AIDS diagnosis

38

Table 4. Relative survival from HIV to AIDS diagnosis during
1996 – 2003, by 25 US States
40

Table 5 Model comparison:
Estimated excess hazard ratios and standard errors of the
log excess hazard ratio
42

viii

LIST OF FIGURES

Figure-1. Maximum likelihood tree of HIV

44

Figure-2. Survival analysis after AIDS diagnosis by race/ethnicity

45

Figure-3. Survival analysis after AIDS diagnosis by age group

46

Figure-4. Survival analysis after AIDS diagnosis by transmission
category

47

Figure-5. Survival analysis after AIDS diagnosis by diagnosis year

48

Figure-6 Survival analysis after AIDS diagnosis by sex

49

Figure-7 Survival analysis after AIDS diagnosis by CD4 count

50

Figure-8 Survival analysis after AIDS diagnosis by HIV viral load

51

1

CHAPTER 1. INTRODUCTION

1. History of HIV Infection
From late the 1970s to early 1980s in the United States and Europe, the emergence
of immunologic dysfunction among patients of unknown etiology attracted popular
attention [1]. Following the unusual occurrence of Pneumocystis carinii pneumonia (PCP)
in five homosexual men from Los Angeles was reported to the Centers for Disease Control
and Prevention (CDC) in 1981 [2], several similar reports, describing male homosexuals
and intravenous drug users with impaired immune systems and T lymphocytes were sent to
CDC [3]. Because more than 90% of these cases occurred in homosexual or bisexual men,
the new term “gay-related immunodeficiency” (GRID) was coined. However, in 1982,
hundreds of similar cases of AIDS had been reported, not only in homosexual and bisexual
men, but also in intravenous drug users, hemophiliacs, blood-transfusion recipients,
heterosexual adults from the Caribbean and Central Africa, sex partners of infected
patients, and infants born to mothers with the syndrome. The common symptoms of the
AIDS patients were due to the depletion of CD4+ T-lymphocyte subset.
The similar epidemiological pattern implicated that a new emerging disease was
transmitted by a novel pathogen in contaminated blood or fluid through sexual intercourse
and other contact with an affected individual. In AIDS patients, the presence of
lymphadenopathy in many affected individuals was reminiscent of the clinical course
related to human viral pathogens, the attention was focused on viruses to infect cells of the
immune system. Several candidate viruses were isolated, including cytomegaloviruses
(CMVs), and human T-cell leukemia virus type-I (HTLV-I) [4]. In 1983, scientists at the
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Pasteur Institute discovered a virus from the lymph nodes of an asymptomatic individual;
the scientists presented their discovery with Gallo and colleagues at the National Institutes
of Health [5]. Subsequently Gallo reported the isolation of retroviruses from AIDS patients,
which they named HTLV-III. In 1994 Levy et al reported a similar retrovirus isolated from
both AIDS patients and healthy individuals from the various risk groups [6] which they
named the AIDS-associated retrovirus (ARV). The new retrovirus, associated with AIDS
in the United States, Europe, and central Africa and exhibiting typical morphologic and
genetic characteristics of the Lentivirus genus, was named human immunodeficiency virus
(HIV) [7], and subsequently HIV-1. In 1986, a related, but immunologically distinct and
less pathogenic human retrovirus (now called HIV-2), was recovered from individuals
residing in several Western African countries [8].

2. Epidemiology

The HIV pandemic is one of the most notorious infectious disease epidemics in
human history. Its morbidity and mortality rates are staggering. In 2001, there were 36
million HIV-infected individuals worldwide [9]. In 2005, it was estimated that 38.6 (range
35~46) million people worldwide were living with HIV. More than 21.8 million deaths
have been due to HIV infection since the beginning of the epidemic [9]. In 2005 alone,
3.4~4.2 million people died of AIDS and nearly 4.1 (range 3.4~6.2) million individuals
worldwide acquired HIV infection [9]. There were an estimated 925,000-1,025,000
persons living with HIV/AIDS at the end of 2003 in the US., and approximately 40,000
new HIV infections occur each year [10]. HIV is transmitted by:
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•

mucosa contact (oral, rectal, or vaginal)during sex;

•

transfusion of HIV contaminated blood products, use of contaminated equipment ; and

•

maternal-fetal circulation or by breast feeding.
Sexual transmission accounts for more than 90% of HIV infections worldwide [10].

Transmission of HIV is dependent on behavioral and biologic factors. The probability of
male-to-female HIV transmission during vaginal sex is approximately 0.1% to 0.2% per
contact; receptive anal intercourse is associated with a considerably higher risk (0.82/per
contact ) of HIV transmission [11]. Risk factors (variables) associated with transmission
included the genetic background of the host, the size of the injured mucosa, and the local
environment in which the exposure occurs.
With the advent of highly active antiretroviral therapy (HAART), the morbidity
and mortality rates of HIV infection are decreasing dramatically in Europe and the USA
[12]. However, in some of Africa and Asian countries, HIV morbidity and mortality rates
are increasing due to the ineffective implementation of prevention and intervention policies
[13].

3. Clinical Manifestation

Usually, HIV infection includes a long period (approximately 10 years) of clinical
latency between the time of primary infection and the development of symptoms indicative
of advanced immunodeficiency. The clinical symptoms of HIV infection were evolved on
the depletion of CD4+ T-cell lymphocytes and the replication of HIV RNA. In the acute
and early stages of the disease, there are some “flu-like” and “mononucleosis-like”
illnesses, such as fever, rash, pharyngitis, and “lymphadenopathysis-like” illnesses.
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Additionally,

myalgias,

arthralgias,

diarrhea,

nausea,

vomiting,

headache,

hepatosplenomegaly, weight loss, thrush, and neurological symptoms may appear. For
patients developing symptoms during primary HIV infection, the mean duration of
symptoms is 3 weeks [14].

When CD4+ T-cell count falls below 500 cells/uL, the following symptoms can be
observed: oropharyngeal, recurrent vulvovaginal candidiasis, bacillary angiomatosis
(usually due to infection with Bartonella henselae), recurrent or multidermatomal herpes
zoster, listeriosis, infections due to Rhodococcus equi, pelvic inflammatory disease, oral
hairy leukoplakiaassociated with EBV, cervical dysplasia (usually associated with human
papillomavirus infection), constitutional symptoms such as unexplained fever or diarrhea
lasting more than 1 month, idiopathic thrombocytopenic purpura, and peripheral
neuropathy.

In late stage of HIV infection, when CD4+ T-cell count is below the level of
approximately 200 cells/uL, cellular immune responses are tremendously suppressed.
Which cause many opportunistic infections, such as chronic microsporidiosis,
gastrointestinal infection with Cyclospora cayetanensis, disseminated Penicillium
marneffei infection (endemic to southeast Asia), cerebral or disseminated Trypanosoma
cruzi infection (endemic to Latin America), relapsing or chronic visceral leishmaniasis,
anal carcinoma, and EBV-positive cases of leiosarcoma, leiomyosarcoma, and Hodgkin's
disease. The increased risk in developing AIDS-defining illnesses associated with a CD4+
T-cell count of less than 200 cells/uL led to the 1993 revision of the CDC definition of
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AIDS, which includes a low CD4+ T-cell count (<200 cells/uL) as an AIDS-defining
criterion [15].

4. Biology
Human immunodeficiency virus (HIV) is a member of the retrovirus family in the
retroviridae (1). HIV is a genetically diverse population of viruses that is responsible for
causing AIDS in much of West Africa (referred to as HIV- 2), and causing AIDS
throughout the rest of the world referenced as HIV-1 (1).
Based on the nucleotide acid sequence of complete viral genomes, HIV-1 was
subsequently defined and classified into three groups: M (major), O (outlier), and N (nonM or O). The M group of HIV-1, which includes over 95% of the global virus isolates,
consists of at least eight discrete clades A, B, C, D, F, G, H, and J (see the maximum
likelihood tree in Figure 1).
The first step for HIV to infect a target cell is to bind the HIV receptor and
coreceptors expressed on the surface of the target cells (such as T help lymphocytes, which
are called as CD4+ T-helper/inducer subset of lymphocytes, abbreviated as CD4+ T-cells
or CD4). Consequently, the main cellular targets for HIV-1 are the CD4+ T-helper/inducer
subset of lymphocytes, CD4+ cells of macrophage lineage, and some populations of
dendritic cells.
In order to quantitatively measure the amount of HIV in serum of HIV-infected
patients, many technologies were developed, the commonly recognized method was
polymerase chain reaction (PCR), the copy number of HIV RNA per micro liter serum
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could be used as a rapid and sensitive measure of viral load, the copy number of HIV RNA
in serum was often referred as HIV viral load [16].

HIV infection can cause the selective depletion of CD4+ cells, therefore, CD4+ Tcell count and HIV viral load are two of the most important variables to predict the
clinical prognosis of HIV-infected subjects.
5. Laboratory Diagnosis
The specific biomarkers (antigen and antibodies) of HIV infection can be captured
by serologic tests. Commonly, Enzyme-Linked ImmunoSorbent Assay (ELISA) was the
preliminary screening test for HIV infection. Because ELISA often generates some false
positive results, a positive ELISA test must always be followed by a confirmatory Western
blot assay [17].

The ideal diagnosis marker of HIV infection should be easily and

reproducibly measurable in all individuals with the disease. Furthermore, it should worsen
with progression of disease and improve with positive responses to therapy.
CD4+ T cell count is the “Marker of Immune System Dysfunction” [18]. CD4+ T
cells are the primary targets of HIV infection. Depletion of CD4+ T cells is the
immunologic hallmark of HIV disease progression. Measurement of CD4+ T cells should
be an excellent marker of disease progression. Some investigations have demonstrated that
the CD4+ T-cell count is a powerful predictor of the short-term risk of developing an
AIDS-defining illness [19]. CD4+ T-cell counts frequently increase in response to
antiretroviral therapy, and this salutary response has been used as a criterion in the
licensing of new anti-HIV drugs. A number of other indicators of immune dysregulation
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correlate with HIV disease progression. The percentage of peripheral blood CD8+ T cells
bearing the activation marker CD38 is positively correlated with disease progression [20].

Measurement of the CD4+ T-cell count yields information regarding the degree of
immunodeficiency; quantification of HIV RNA in plasma obtains the information related
to the rate and severity of immune deficiency. Technology currently available for
reproducible measurement of plasma viremia in clinical specimens includes PCR, RT-PCR,
nucleic acid sequence–based amplification (NASBA), and branched DNA (b-DNA) assays.
The plasma viremia level of more than 100,000 HIV RNA copies/mL at 6 months after
seroconversion was associated with an odds ratio of 10.8 for the development of AIDS.
The level of plasma viremia at 7 to 12 months after seroconversion was a strong predictor
of CD4+ T-cell depletion during follow-up [1, 19].
Current recommendations regarding the initiation and maintenance of antiretroviral
therapy rely heavily on the two best laboratory markers for HIV disease progression, the
CD4+ T-cell count and the HIV viral load [21-22].

6. Treatment and Prevention

Highly active antiretroviral therapy (HAART), a single or combination of several
drugs, has high activity to inhibit HIV RNA replication. HIV cocktail therapy is a
combination reagent, which inhibits the replication of HIV RNA at different steps of HIV
life-cycling.

The currently available HIV inhibition reagents can be categorized into

reverse transcriptase inhibitors, protease inhibitors, and integrated zinc-finger inhibitors.

8
Inhibitors of viral reverse transcriptase (RT) like zidovudine and lamivudine were the first
agents to be developed for the treatment of HIV infection. The protease inhibitors, such as
saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, and lopinavir, are all potent
antiretrovirals, particularly when used in combination with nucleoside analog RT inhibitors
(NRTIs) [23].
Adherence to an antiretroviral treatment is a complex issue since antiretroviral
regimens are multiple agents, and must be taken indefinitely in most cases. Many of the
drugs have intolerable side effects and toxicities (nausea, vomiting, and/or diarrhea).
Lapses in adherence provide the opportunity for virus replication, and enhance the
probability of the emergence of drug-resistant virus mutants. Another insurmountable
challenge for therapy is the presence of an HIV latent reservoir in resting CD4+ memory T
cells [24].

A treatment regimen should be selected that will afford a high likelihood of longterm profound suppression of plasma viral load and a significant increase in the CD4+ Tcell count. Currently, the most useful prophylaxis strategy for HIV infection is to stop the
virus transmission:

condom use, blood screening, and preventing mother to child

transmission.
An effective weapon in preventing further spread of the HIV epidemic will be a
safe and effective vaccine. Even though tremendous efforts have been made and several
promising candidate vaccines have been generated, there are huge unknown puzzles that
remain to be elucidated in this field.
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7. Statistical Advances and Challenges in HIV/AIDS Modeling
Many statistical methodologies have been developed for modeling the HIV epidemic [25,
26], new therapies (HAART), prophylaxis strategies [27, 28], and HIV incidence [29-32].
Many of challenges remain to be elucidated by collaborative efforts from mathematicians
, biologists and epidemiologists. For the treatment of HIV infection, the common
philosophy is: “treat early and treat hard” [22, 23].

Because HIV genetic divergent

mutants emerge constantly, the corresponding treatment and prevention methods need to
be created accordingly. Therefore, it is indispensable to develop and identify optimal
treatment strategies for HIV-infected individuals. How to determine an optimal treatment
regimen is a great challenge. At present, there are a large number of treatment options,
statisticians need to help clinicians figure out the following questions:
What is the best initial treatment combination?
When is the best time for a certain patient to switch from one regimen to another?
What multi-drug treatment sequence generates the best treatment effect?

Another statistical challenge is to estimate the efficacy of intended treatment. Since
many potential treatment strategies become available, the reported promising new dugs
may coincide with relevant clinical trials in progress. Thus, the patients may be attracted to
withdraw from the trials to which they are party. The investigators may change the initial
protocol to reflect the new achievement. Under this circumstance, the intend-to-treat rule
may not generate unbiased estimation [33].
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The most commonly used bio-markers, CD4+ T-cell count and viral load, are subject to
high variability during disease progression. It is necessary to measure them repeatedly over
time for each patient. The treatment efficacy on the marker progress can be estimated by a
standard multivariate model or mixed model. CD4+ T cell count and HIV viral load often
have missing values due to the death of patients or loss of follow up. Several nonparametric methods have been developed for solving the missing data problem [34, 35].

8. HIV/AIDS relative survival and mean residual life analysis
Conventionally, net or crude survival was employed to analyze and predict patients’
clinical disease progression after diagnosis. Recently, relative survival has become a very
popular survival analysis method for cancer patients [36-38]. The prerequisite for net or
cause-specific survival analysis is that fact of death information should be available. For
HIV infected patients, it will generate some confusion when net survival is selected to
extrapolate the survival of HIV-infected patients. According to the CDC 1993 definition,
factors other than HIV infection can cause death of AIDS patients. HIV-infected patients
have different opportunistic infections (OIs) as well as divergent co-infection (HBV, HCV,
CMV, HPV, HSV). It is not a rare event that causes other than HIV infection will appear in
the death certificates of AIDS patients. Therefore, it is more realistic to use relative
survival to model and analyze disease progression of HIV/AIDS patients [38, 39]. For
HIV/AIDS patients, relative survival is estimated as the ratio of observed survival of the
HIV/AIDS patients (where all deaths are considered as events) to the expected survival of
the general population, matched to the patients with respect to the main factors (age, race,
sex, calendar year ) and assumed to be free of HIV infection.
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Mean residual life is a measurement of the remaining life expectancy of a subject at time t,
which is the remaining survival time given the subject surviving up to t. It has been widely
applied to many fields [40].
Since relative survival analysis can be used to identify the determinant factors of
HIV/AIDS clinical progression, it has been taken as a reliable approach to estimate the
efficacy of prophylaxis and treatment strategies of HIV-infected subjects. However,
inconsistent results have been reported from different cohort studies. The inconsistency
was related to the divergence of sample size, follow up time periods and the failure to
correct important co-founding variables. In this study, we will conduct systematic and
comprehensive relative survival and mean residual life analyses of HIV/AIDS patients
with the most recent data from the United State National HIV/AIDS reporting system
(HARS).
In chapter II, we describe the methods for data analysis. Chapter III includes data analysis
and results. Chapter VI contains the discussion. Chapter V includes conclusions for this
study. Chapters VI, VII, VIII, and IX are references, tables, figures, and appendixes
respectively.

CHAPTER II. METHODS

1. Data Source
1.1. Definitions
HIV-infected patients (HIV): For most HIV-infected patients, HIV infection
time is unknown. The HIV patient’s diagnosis information in HARS is the date of first
HIV positive test

(HIV seroconversion time). The primary screening test of HIV
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infections is called as Enzyme-Linked ImmunoSorbent Assay (ELISA). The confirming
test of HIV infection is Western blot. After the positive ELISA test of HIV
antigen/antibody, if the Western blot test is also positive, then the patient is considered
HIV infected.
AIDS patients (AIDS): According to the CDC case definition, one has AIDS if
he/she is infected with HIV and presents with one of the following:
(1) A CD4+ T-cell count below 200 cells/µl (or a CD4+ T-cell percentage of total
lymphocytes of less than 14%), or
(2) He/she has one of the common defining opportunity illnesses [15].
1.2. Datasets Used in the Study
Data of 1996-2003 diagnosed AIDS patients were from the U.S. national HARS,
including all 50 United States; 1996-2003 diagnosed HIV cases were from 25 states
(Alabama, Arizona, Arkansas, Colorado, Idaho, Indiana, Louisiana, Michigan, Minnesota,
Mississippi, Missouri, Nevada, New Jersey, North Carolina, North Dakota, Ohio,
Oklahoma, South Carolina, South Dakota, Tennessee, Utah, Virginia, West Virginia,
Wisconsin, and Wyoming). Data used in this study satisfy the following criteria:
•

Inclusion criteria:
(1) AIDS patients were from the HARS.AS_JUN06 dataset: N = 976,105
observations, 614 variables.
(2) Laboratory

data

from

the

LAB.RA_JUN06

dataset:

N=

1,418,260

observations ,351 variables.
(3) HIV patients from the HARS.HS_JUN06 dataset: N= 266,437 observations,
613 variables.
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•

Exclusion criteria:
(1) HIV/AIDS patients diagnosed at age <13 years.
(2) HIV infection diagnosis year or month was missing.
(3) AIDS diagnosis year or month was missing.
(4) HIV/AIDS patients’ death year or month was missing.
(5) HIV/AIDS diagnosis year was <1996 or > 2003.

•

Follow up: patients were followed up through the end of 2005. The maximum follow
up time was 10 years.

The observed survival probabilities of AIDS patients were calculated by using the KaplanMeier method for the corresponding datasets. The expected survival probability was
obtained by merging the national population data and mortality datasets sorted by age, sex,
race/ethnicity, and calendar year. Both the population denominators and numerator
mortality rate were from the National Center for Health Statistics [41]. The death rate in
2005 was not available and was therefore assigned to be the same value as that in 2004 in
the analysis. The maximum age in the mortality dataset was 85 years. So if a person’s age
in the population dataset is over 85 years, his\her age will be assigned as 85 years.
2. Models and Estimation Approaches of Relative Survival and Mean Residual Life
2.1. Models of Relative Survival
For HIV/AIDS patient with covariate vector z, the hazard rate at time t is modeled
as the sum of the expected hazard rateλ*(t; z) and the excess hazard rate v(t; z) due to a
diagnosis of AIDS:
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λ( t; z ) = λ*(t; z) + v(t; z) ,

(1)

where the expected hazard (sometimes called the baseline hazard) is estimated from
general-population mortality rates.
The corresponding survival function can be written as:

S(t; z) = S*(t; z) r(t; z), or r(t; z) = S(t; z) / S*(t; z ),

(2)

Where r(t; z) is the relative survival.
If the excess hazard rate, v(t; z), is assumed to be a multiplicative function of the
covariates, written as exp(z’β), then the model for the relative survival of patients with
HIV/AIDS diagnosis is :

λ (t; z) = λ*(t; z) + exp(z’β ),

(3)

where β is an unknown parametric vector. Based on the equation (3), estimation methods
of relative survival were developed in references [42-44] with full likelihood and
generalized linear model (GLM) approaches.

2.2. Estimation Approaches of Relative Survival Analysis [45]
Four approaches can be applied to estimate the relative survival with the dataset of
AIDS to death (339,863 AIDS patients, diagnosed from 1996 to 2003, followed up through
the end of 2005):
(1) Grouped survival times, GLM with a binomial error structure ;
(2) Grouped survival times, GLM with a Poisson error structure ;
(3) Exact survival times, individual subject-band observations;
(4) Exact survival times, collapsed data, GLM with a Poisson error structure.
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The collapsed data used in the fourth approach contained the same number of
observations as the grouped data sets. The distinction between collapsed data and grouped
data is that, in the collapsed data, y (person time, years at risk using exact times yi) and
d* (d* expected death number) are based on the exact time at risk whereas these
quantities are approximated for grouped data.
The selected models were fitted with AIDS patient data and the general-population
mortality rates. The excess hazard ratios, or relative excess risks, are assumed to be an
exponential function of unknown parameters [46]. An excess hazard ratio of, for example,
1.5 for a patient with HIV viral load 2 unit, compared to a patient with HIV viral load 1
unit means that the excess risk of death will increase 50% if the HIV RNA copy number
in peripheral blood increases 1 unit.

2.3 Relative excess hazard ratio and AIDS free survival proportion

Model (4) was used to estimate the main effect for each variable adjusted for all of the
other variables in the model. The first level of each variable was set up as reference level.
After obtaining the main effect of each level, the relative excess hazard ratio was the
exponentiated rate of the effect for the corresponding level to the referenced level. AIDS
free survival proportion was calculated using the Kaplan Meier method.

2.4 Modeling and Estimation of HIV/AIDS Mean Residual Life
Mean residual life is a measurement of the remaining life expectancy of a subject at time t,
which is the remaining survival time given the subject surviving up to t. Dr. Qin and Dr.
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Zhao’s methodology was employed to model the distribution of HIV/AIDS mean residual
life [40].
3. Variable Selection and Model Checking
The AIDS to death cohort dataset was used for model building. The dataset has
976105 observations, 614 variables, plus the variables (CD4+ T cell count, HIV viral load
as well as CD4+ T-cell count detection times) from the laboratory dataset; the total variable
count was 663. Based on published papers [22, 38], sex, age group, race, transmission
category, HIV/AIDS diagnosis year, CD4+ T-cell count, viral load were selected for
inclusion in our model. These variables have a close relationship with disease development
and clinical progression. In our dataset, the HIV viral load has a large amount of missing
(57.3%); CD4+ T-cell count information has 14.2% missing (see the discussion).
The selected approaches (see table 5 for detail) (1), (2) and (4) are generalized
linear models. They can be checked by the deviance statistic which is a measure of
goodness-of-fit [43]. Excess hazard in approaches (1), (2), and (4) require the assumption
of proportional hazard in a pre-specified interval band, so each variable will be tested using
the log rank test.
All the analyses were implemented using SAS 9.1 program, except that the analysis
of HIV/AIDS means residual life was performed using S-plus version 7.0.

CHAPTER III. DATA ANALYSIS AND RESULTS

Three datasets were generated: 339,863 AIDS cases were selected for the study of
AIDS to death; for the HIV sero-conversion (HIV) to death study, 122,391 HIV-infected
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patients were selected; for the HIV sero-conversion (HIV) to AIDS study, 122,379 HIVinfected patients were selected.

1. Variable selection and survival curve analysis
The log rank test was used to check the significance of seven preliminary selected
variables: race/ethnicity (non-Hispanic white (white), non-Hispanic black (black), Hispanic,
Asian/Pacific Islander (A/PI), and American Indian/Alaska Native (AI/AN)), age at
diagnosis, sex (male and female), diagnosis year, HIV transmission category (men who
have sex with men(MSM), male drug user, female drug user, men sex men and drug user,
female high risk heterosexual contact, male high risk heterosexual contact, CD4+ T-cell
count, and HIV viral load.
For variable selection, survival curves were plotted by each risk factor to check
equality over strata for the proportional hazard assumption. Figure 2 shows that Blacks and
AI/AN had worse survival probabilities compared with A/PI. Figure 3 shows that there is
an obvious monotonous trend among the age groups. The survival probability of AIDS
patients decreases when age increases. Figure 4 shows that the survival probabilities from
highest to lowest transmission categories are: male to male sex (MMS, similar to MSM),
female high-risk heterosexual contact (HCF), male high-risk heterosexual contact (HCM),
unknown risk group, MSM and injection drug use (IDU), male injection drug use (IDUM),
female injection drug use (IDUF). Injection drug users are the highest risk AIDS
transmission group. Additionally, from Figure 4, the assumption of proportional hazard
was not valid for the variable transmission category. After adding interaction terms (MSM
with IDU, HCM vs HCF), the assumption of proportional hazard was valid. From Figure 5,
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we observe that patient survival was better when AIDS was diagnosed later in time (e.g.,
2003 versus 1996). Figure 6 shows that the survival curves of males and females are very
similar. Figure 7 indicates that the survival probability of AIDS patients would improve
with increased CD4+ T-cell count (first CD4+ T-cell count within 6 months of AIDS
diagnosis). Figure 8 shows that with the increased viral load (first available record), the
survival probability among AIDS diagnosed patients decreased.

2. Relative survival from AIDS diagnosis to death
Table 1 provides the results of relative survival probabilities from AIDS diagnosis
to death. There were 339,863 persons diagnosed with AIDS at age >= 13 years in the 50
states and the District of Columbia from 1996 to 2003. Forty eight percent of the AIDS
patients were black, 31% were white, 20% were Hispanic, and less than 1% were A/PI or
AI/AN (Table 1, columns 2, 3). The number of male AIDS patients was 3 times the
number of females. Seventy two percent of patients were from 30 to 50 years old. Twenty
seven percent were diagnosed with AIDS at very low CD4+ T-cell counts (<50 cells/uL).
Hispanic and Black AIDS patients have lower relative survival probability
compared with white patients. AI/ANs have the lowest relative survival probability.
Generally, with the increase of age at AIDS diagnosis and viral load, the relative survival
rate among AIDS-diagnosed patients decreases; while with increasing CD4+ T-cell count
in peripheral blood, the relative survival probability increases.

The difference of the cumulative relative survival probability between men and
women was small; women had slightly higher survival at one year and slightly worse at
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three years after AIDS diagnosis compared with men. One and three years after AIDS
diagnosis, MSM had the highest cumulative relative survival probability compared with all
the other transmission categories. Injection drug users had the worst relative survival
probability. From 1996 to 2003, each year the survival of newly diagnosed AIDS patients
was slightly better, even though year to year improvements were not significant.

3. Relative survival from HIV infection diagnosis to death

Table 2 gives the results from HIV diagnosis to death for cases diagnosed from
1996 to 2003 in 25 states using integrated HIV/AIDS surveillance reporting system. Fifty
percent of HIV patients were black, 34% were white, 8.5% were Hispanic, and less than
1% was Asian/Pacific Islander or American Indian/Alaska Native (Table 2, columns 2, 3).
The number of males was almost 3 times the number of female HIV patients (males
account for 72%, females 28%). Over sixty percent of HIV patients were aged from 30-49
years; twenty three percent were 20-29 years old. Sixteen percent were diagnosed with
HIV at very low CD4+ T-cell conut (<50 cells/uL).
The differences of the cumulative relative survival rates among race/ethnicity, sex
and diagnosis year can be seen in Table 2 (column 4 for 1-year and column 6 for 3-year
cumulative survival). Similar to AIDS, HIV patients diagnosed at older ages had lower
relative survival rates compared with those diagnosed at younger ages. Among different
transmission categories, the injection drug users had the lowest relative survival. HIV
infected patients with higher CD4+ T-cell count also had better survival, but this
information was missing for 25% of patients. If the HIV patients had lower viral loads,
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they would have higher relative survival. Fifty one percent of patients did not have viral
load test results.

4. Relative excess hazard ratio

Table 3 presents the results obtained by using the estimation approach (4). Columns
2 and 4 present the relative excess hazard rate for AIDS and HIV patients respectively. The
excess hazard rate of death for black, Hispanic, and AI/AN with AIDS and HIV patients
were investigated after adjustment for sex, age, transmission category, diagnosis year,
CD4+ T-cell count as well as HIV viral load. For each category, the first level was used as
the reference level. For race, HIV infected AI/AN patients have the highest relative excess
hazard rate (1.41 and 1.37 for AIDS and HIV, respectively). A/PI AIDS cases had the
lowest relative excess hazard rate (0.95 and 0.91 for AIDS and HIV, respectively). In
contrast to the corresponding circumstance in relative survival analysis, the relative excess
hazard rates of AIDS to death and HIV to death increased with the increase of age at AIDS
diagnosis. If HIV viral load increased, then the relative hazard rate for AIDS and HIV
patients increased; while with increasing CD4+ T-cell count, the relative excess hazard
rates decreased. From 1996 to 2003, each year the relative excess hazard rate of newly
diagnosed AIDS and HIV decreased slightly. For certain variables (such as race/ethnicity),
compared with HIV, all the AIDS patients had higher relative excess hazard rate except
age group. The relative excess hazard rate for the oldest 60+ year AIDS patients was 6.93
(95% CI: 5.94 to 8.09); while for HIV patients, it was 20.14 (95% CI: 14.5 to 28.1).
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5. AIDS free survival proportion from HIV to AIDS diagnosis

From Table 4, we can see that among 122,379 patients diagnosed with HIV from
1996 to 2003, 64,423 progressed to AIDS before the end of 2003. Among 2003 HIV
diagnoses, after 12 months, 60% of the patients had not progressed to AIDS; after 36
months, 56% had not developed AIDS. Sixty percent of women had not progressed to
AIDS 3 year after HIV diagnosis; while 50% HIV infected males had developed AIDS
during that time frame.
HIV infected A/PIs were least likely to have developed AIDS 3 years after HIV
diagnosis compared with Blacks, Hispanics, or American Indians/Alaska Natives. The
AIDS-free rate of patients diagnosed with HIV at younger ages was higher compared with
those diagnosed with HIV infection at older ages for both 1 and 3 year after HIV diagnosis.
Among transmission categories that affect both men and women, the AIDS-free survival
rate at 36 months was higher for women than for men. The AIDS-free survival rate did not
change substantially between diagnosis year, but did improve from 1996 to 2003 (50.0 to
55.9 for 3 years after HIV diagnosis). AIDS-free survival probability decreased with
increasing HIV viral load, when HIV viral load was up to 5, the AIDS-free survival
probability decreased dramatically.
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6. Model comparison and model checking
Table 5 shows that the main effect for each variable had no obvious difference
when estimated by different models (the values of main effect are similar for a single
variable from different models). Model 1 was developed based on equation 9. Assuming
that the number of deaths in each interval follows a binomial distribution, the outcome is
l ki − d ki (the number of patients surviving the interval), with binomial error structure with
denominator l ki . Model 2 was built based on grouped events (deaths) with approximate
survival time. The number of deaths in a pre-specified time interval band (length = 1 year)
follows a Poisson distribution with approximate survival time. Model 3 was developed
based on the assumption that the number of deaths in a pre-specified interval band (length
= 1 year) follows a Poisson distribution, but the data are individual level and survival time
is the exact time. Model 4 was generated from the assumption that the number of deaths in
a pre-specified interval band (length = 1 year) follows a Poisson distribution, the data are
from grouped level and survival time is exact. The goodness of fit test for selected
approaches has p a value greater than 0.05, so there is not enough evidence to reject the
current models, thus our data fit the models well.
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CHAPTER 4. DISCUSSION

HIV infection prevention is one of the most challenging tasks for public health
workers. In order to improve the quality of life of HIV-infected patients and extend the
interval from HIV infection /AIDS diagnosis to death, the US Department of Health and
Human Services has implemented the use of many prophylaxis, intervention strategies and
methodologies, such as mass media campaigns, peer education about HIV transmission,
treatment of other sex transmitted infection, condom social marketing, safe blood provision,
and needle exchange. Survival analysis is not only a conventional technology but also a
frequently implemented technique to evaluate the efficiency of new treatment and
prevention methods. Relative survival was a very popular cancer survival analysis
technique; the first advantage is that it does not need the information of the specific cause
of death.

Another advantage is that relative survival analysis excludes the effect of

baseline mortality (such as old age) on the survival rate under study [47, 48]. Compared
with cancer studies, this population-based survival analysis recently began to attract the
attention of HIV/AIDS researchers [37, 38]. HIV/AIDS relative survival analysis will
provide a measure of the excess mortality experienced by patients diagnosed with HIV
infection or AIDS, irrespective of whether or not the excess mortality is directly or
indirectly attributable to HIV infection.
Our results showed that the relative excess hazard of death was higher for blacks,
American Indian /Alaska Natives, as well as Hispanics with HIV infection and AIDS
diagnosis as compared with whites. Excess risk for death also was higher for persons with
a diagnosis of HIV or AIDS at an older age, and lower CD4+ T-cell count at diagnosis.
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Additionally, if HIV/AIDS patients have a higher viral load, they will have a higher
relative excess hazard rate compared to the HIV/ AIDS patients, who have a lower HIV
viral load.
CD4+ T-cell count is one of the most commonly used surrogates for disease
progression [49, 50] and disease severity/immune dysfunction as well as a criterion for
evaluation of the effect of clinical and prophylaxis intervention applied in HIV/AIDS
patients. Usually, the variable data on this marker is characterized by unequal numbers of
unevenly spaced repeated observations. In our data set, a patient can maximally have up to
20 times CD4+ T-cell count values. Almost half of patients have no CD4+ T-cell count
information (48%) (the time interval between any two time CD4+ T-cell count values is
different for each patient). CD4+ T-cell count has many components of variability:
measurement error, short term variability, and long term trend. To avoid the correlation
among repeated CD4+ T-cell count in one subject, we used the first CD4+ T-cell count in
our model after disease diagnosis but within 6 months of HIV infection or AIDS diagnosis.
Further investigation is needed to determine the effect of the missing data of CD4+ T-cell
count on results. Since 1996, using HIV viral load as an independent predictor variable to
predict outcome (disease progression, treatment) has attracted wide attention [1, 51]. The
results from our study are similar to previous publications: the higher HIV RNA viral load,
the lower survival probability [1, 51].
Similar results were obtained from our analysis and other research about the effect of
diagnosis age for HIV/AIDS as an important determinant of disease progression. Our
results show that younger patients have the advantage of surviving longer than older
patients. It was reported that younger age favored CD4+ T-cell restoration upon HAART,
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which is consistent with younger persons having good thymic function for CD4+ T-cell
generation [1]. With respect to the transmission categories, IDUs had lower relative
survival probability (higher relative hazard rate) 36 months after HIV infection and AIDS
diagnosis than other transmission categories. Independent of HIV infection, IDU patients
have an increased risk of death from overdose, violent causes, HCV co-infection, liver
toxicity, or a decline of adherence of treatment [38]. All of these risk factors might
contribute to this transmission category pattern. Between men and women, there was no
significant difference in relative excess risk for death and the relative survival.
The disparities of the AIDS-free survival probability in our analysis may relate to
access or adherence to treatment or diagnosis delay, or lack of adequate care. If AIDS
diagnosis is delayed in disadvantaged population groups (e.g., Hispanics), then it is
difficult to obtain a precise estimate of the AIDS-free probability difference (between
Hispanics, blacks, and whites) if it exists.
The advantage of relative survival analysis is obvious for HIV/AIDS survival studies.
In the cohort dataset of HIV to death, it was found that 15% of HIV patients were dead
before AIDS diagnosis. These patients were not dead from AIDS defining events; secondly,
we do not need the cause-specific information of death, which can be biased toward under
ascertainment of HIV/AIDS as a cause of death, to perform relative survival analysis.
For model selection, generalizability depends on independent predictors. Our model
included the most important progress factors so far identified. From the point of model
simplicity, we did not include genetic factors (MIDR1, 3435C/T polymorphism, CCR5)32
mutation), which have been shown to affect response to antiretroviral therapy [52].
Consideration of the specificity of survival data (events may count at pre-specified

26
intervals or at the exact survival time), four approaches were tested to model the relative
excess hazard of death by using the AIDS to death cohort dataset. Similar results for
estimating the relative survival were obtained when using different models. This is not
surprising since similar methods and datasets were used to model the relative survival of
AIDS patients. Model (1) was based on a binomial assumption. Model (2) used grouped
data (events were counted in approximate survival time). Model (3) used individual level
of data. Finally, model (4) used collapsed events obtained from exact survival time.
The relative survival results of Table 1, 2 and 3 were obtained with the generalized
linear model (model 4) based on collapsed data with exact survival times and a Poisson
assumption. The resulting Goodness of fit test showed that our data fit well for the selected
model 4, with a deviance/df of 0.7799. Meanwhile, two term interactions were tested. It
was found that there were significant interactions between age and year of follow-up (fu),
age and diagnosis year (dxyr). The main effects of follow-up year and sex are not
significant in the model, thus, they should be excluded from the final model. The final
model may include age, race/ethnicity, transmission category, CD4+ T-cell count, viral
load, and the two interactions fuXage and fuXdxyr.
The approach developed by Qin and Zhao [40] was used to estimate the mean residual
life for HIV and AIDS patients after survival 12 months after diagnosis. Our results
showed that the estimated mean residual life for HIV and AIDS patients followed the same
pattern as the survival probability: if the HIV and AIDS patient groups had a higher
relative survival probability (or survival probability), then they had a longer mean residual
life (white patients); if the patients had a lower survival probability (injection drug users),
then they had a shorter mean residual life. Compared to the results of survival probability,
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the mean residual life was shorter than expected, especially for newly diagnosed HIV and
AIDS patients. This bias may be associated with the large amount of censoring and the
dependency between censoring and survival time.

More than 80% of AIDS cases

diagnosed in 2003 were censored. A case with a longer survival time has a higher
probability of being censored. Therefore, the results on mean residual life were not shown.
We will continue our efforts to solve this problem in estimating the mean residual life.
Survival analysis is a widely accepted method to evaluate the efficacy of new
treatment and prophylaxis strategies. In our study, the nation-wide HIV/AIDS data was
used to estimate the mean residual life. Mean residual life has the potential to be easily
understood by clinicians. For example, at the time point (t) to implement a new treatment
or a new HIV vaccine (after HIV/AIDS patients surviving 12 months), the mean residual
life is the improved life time of HIV and AIDS patients after using the new treatment or
the new vaccine.
Since only the first time detection data of CD4+ T-cell count and viral load was
included in the model (both CD4+ T-cell count and viral load can be used to reflect disease
stage or severity). One of the limitations in our study was that we did not have information
on the severity of the HIV infection caused disease. Furthermore, over 50% of the viral
load information was unknown. Secondly, for most patients, HIV infection time was
unknown, we used HIV seroconversion time to replace HIV infection time, which may
cause a slight difference in the survival analysis from HIV infection to AIDS/death. Finally,
The data used to assess relative survival among persons with an HIV diagnosis (with or
without a concurrent diagnosis with AIDS) or assess disease progression from HIV
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diagnosis to AIDS included 25 states; and it is not known whether results can be
extrapolated to the United States as a whole.
Further efforts are needed to address whether differences in survival and mean
residual life are the result of treatment and/or prevention interventions. CD4+ T-cell count
obtained at different time points need to be incorporated in models describing the full
scenario of disease progression. HIV viral load as an independent variable to predict
survival and mean residual life deserves further investigation.

Chapter 5. CONCLUSIONS
•

Generalized linear model with Poisson error structure was an appropriate approach for
estimating the relative survival of HIV/AIDS patients.

•

Younger persons, MSM, and whites have better survival compared to older, IDUs,
blacks, and Hispanics after HIV or AIDS diagnosis.

•

HIV diagnosed patients have higher relative excess hazard compared with AIDS
diagnosed patients.

•

When viral load was larger than log5, the AIDS-free survival probability 36 months
after HIV diagnosis decreased considerably.

•

HIV viral load is a very important risk factor affecting HIV/AIDS survival (its value of
the estimated main effect and the relative excess hazard is highest).

•

It is worthwhile to further the analysis of mean residual life for HIV/AIDS patients.
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Table 1 Relative survival after AIDS diagnosed from 1996 to 2003,
by 50 US States
Characteristics
Race/ethnicity
non-Hispanic white
non-Hispanic black
Hispanic
Asian/Pacific Islander
American Indian/Alaska Native
Age at diagnosis (years)
13-19
20-29
30-39
40-49
50-59
60+
Transmission category
MSM
IDU Male
IDU Female
MSM+IDU
HC Male
HC Female
Unknown
Sex
Male
Female
Diagnosis year
1996
1997
1998

Frequency

Percent

CR1

104104
163154
68196
3063
1346

30.6
48.0
20.1
0.9
0.4

88.8
86.6
86.4
88.0
85.4

2728
43386
137193
107259
36574
12723

0.8
12.8
40.4
31.6
10.8
3.7

120762
50866
23648
18010
40054
20359
66164

CICR1

CR3

CICR3

(88.5, 88.9)
(86.4, 86.7)
(86.2, 86.7)
(86.8, 89.1)
(83.3, 87.1)

81.0
75.2
78.6
82.8
73.2

(80.7, 81.3)
(75.0, 75.5)
(78.3, 79.0)
(81.3, 84.2)
(70.3, 75.9)

96.2
92.2
90.0
85.8
80.2
69.2

(95.4, 96.8)
(92.0, 92.5)
(89.8, 90.1)
(85.7, 86.1)
(79.8, 80.7)
(68.3, 70.0)

89.6
83.8
81.2
76.0
70.0
59.2

(87.6, 91.3)
(83.3, 84.2)
(80.9, 81.4)
(75.7, 76.3)
(69.4, 70.4)
(58.2, 60.1)

35.5
15.0
7.0
5.3
11.8
6.0
19.5

89.8
83.4
86.2
90.8
81.4
85.2
89.0

(89.6, 90.0)
(83.0, 83.7)
(85.8, 86.6)
(90.3, 91.2)
(80.9, 81.7)
(84.7, 85.7)
(88.8, 89.3)

82.8
70.4
71.0
79.8
73.2
76.0
79.6

(82.5, 83.0)
(70.0, 70.9)
(70.3, 71.7)
(79.0, 80.4)
(72.8, 73.8)
(75.3, 76.6)
(79.2, 79.9)

255371
84492

75.1
24.9

87.0
87.8

(86.9, 87.2)
(87.5, 87.9)

78.2
76.4

(78.0, 78.4)
(76.1, 76.8)

58286
47637
40932

17.2
14.0
12.0

84.2
86.8
86.6

(84.0, 84.6)
(86.4, 87.0)
(86.2, 86.9)

71.8
75.4
76.2

(71.4, 72.2)
(75.0, 75.9)
(75.8, 76.7)
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1999
2000
2001
2002
2003
First CD4 CNT
<50
50-99
100-199
>=200
Unknown
Log10(viraload)
1-2
3
4
5
6-8
Unknown
Total

39067
39392
38210
38073
38266

11.5
11.6
11.2
11.2
11.3

87.2
87.8
88.2
88.8
90.0

(86.8, 87.5)
(87.4, 88.1)
(87.9, 88.6)
(88.5, 89.1)
(89.6, 90.3)

77.4
78.4
79.6
81.4
86.0

(76.9, 77.9)
(77.9, 78.8)
(79.2, 80.1)
(81.0, 81.9)
(85.5, 86.3)

91730
43815
96745
59497
48076

27.0
12.9
28.5
17.5
14.2

81.0
88.2
93.6
93.8
77.2

(80.8, 81.3)
(87.9, 88.5)
(93.4, 93.8)
(93.5, 93.9)
(76.8, 77.6)

69.0
77.8
85.4
86.8
67.8

(68.7, 69.4)
(77.4, 78.3)
(85.1, 85.7)
(86.4, 87.1)
(67.3, 68.2)

14052
23872
30966
53801
22321
194851
339863

4.1
7.0
9.1
15.8
6.6
57.3
100.00

98.8
97.6
96.4
93.8
89.8
81.4
87.2

(98.6, 99.1)
(97.3, 97.8)
(96.2, 96.6)
(93.7, 94.1)
(89.5, 90.3)
(81.3, 81.7)
(87.1, 87.3)

96.8
94.0
91.0
86.0
79.8
69.8
77.8

(96.4, 97.3)
(93.6, 94.4)
(90.6, 91.4)
(85.6, 86.3)
(79.1, 80.4)
(69.6, 70.1)
(77.6, 77.9)

CR1: 1-year cumulative relative survival proportion.
CICR1: 95% confidence interval of 1 –year cumulative survival rate.
CR3: 3-year cumulative relative survival proportion.
CICR3: 95% confidence interval of 3 –year cumulative survival rate.
MSM: men who have sex with men.
MSM+IDU: men who have sex with men and injection drug user;
HC: heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;
AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus.
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.
Viraload: HIV RNA copy number.
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Table 2 Relative survival after HIV diagnosis from 1996 to 2003,
by 25 US States
Characteristics
Race/ethnicity
non-Hispanic white
Non-Hispanic Black
Hispanic
Asian/Pacific Islander
American Indian/Alaska Native
Age at diagnosis( years)
13-19
20-29
30-39
40-49
50-59
60+
Transmission category
MSM
IDU Male
IDU Female
MSM+IDU
HC Male
HC Female
Unknown
Sex
Male
Female
Diagnosis year
1996
1997

Frequency

Percent

CR1

CICR1

CR3

CICR3

42120
68386
10358
636
891

34.4
55.9
8.5
0.5
0.7

93.4
93.4
93.2
93.6
92.2

(93.1, 93.6)
(93.1, 93.5)
(92.7, 93.7)
(91.5, 95.3)
(90.1, 93.7)

89.2
87.2
89.2
91.6
85.6

(88.9, 89.6)
(87.0, 87.6)
(88.4, 89.8)
(89.1, 93.7)
(82.6, 88.1)

3822
27824
46412
31021
9949
3363

3.1
22.7
37.9
25.4
8.1
2.8

99.4
97.8
94.6
91.0
85.8
73.4

(99.0, 99.5)
(97.7, 98.0)
(94.4, 94.9)
(90.6, 91.3)
(85.0, 86.4)
(71.9, 75.0)

98.2
95.2
90.2
84.6
77.8
64.6

(97.3, 98.9)
(94.9, 95.5)
(89.8, 90.5)
(84.1, 85.0)
(76.9, 78.7)
(62.6, 66.4)

43745
10859
5276
4248
8756
16315
33192

35.7
8.9
4.3
3.5
7.2
13.3
27.1

94.6
89.8
92.8
95.0
94.6
96.4
90.6

(94.4, 94.9)
(89.2, 90.4)
(92.1, 93.6)
(94.3, 95.7)
(94.1, 95.1)
(96.0, 96.6)
(90.4, 91.0)

90.6
80.6
84.4
88.6
89.2
92.0
85.6

(90.3, 91.0)
(79.6, 81.4)
(83.1, 85.5)
(87.3, 89.6)
(88.5, 90.1)
(91.5, 92.5)
(85.2, 86.1)

88578
33813

72.4
27.6

92.8
94.6

(92.6, 93.0)
(94.4, 94.9)

87.6
89.4

(87.4, 87.9)
(89.1, 89.8)

17716
16569

14.5
13.5

92.0
93.2

(91.6, 92.4)
(92.9, 93.6)

84.8
86.8

(84.1, 85.4)
(86.2, 87.4)
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1998
1999
2000
2001
2002
2003
First CD4 CNT
<50
50-99
100-199
>=200
Unknown
Log10(viraload)
1-2
3
4
5
6-8
Unknown
Total

15229
14324
14924
14543
14862
14224

12.4
11.7
12.2
11.9
12.1
11.6

92.8
93.2
93.6
93.6
94.0
94.2

(92.4, 93.2)
(92.7, 93.5)
(93.3, 94.1)
(93.2, 94.0)
(93.6, 94.4)
(93.7, 94.5)

87.2
87.6
88.6
88.6
90.4
92.4

(86.5, 87.7)
(86.9, 88.2)
(88.0, 89.2)
(88.0, 89.2)
(89.8, 91.0)
(91.9, 92.9)

20443
8628
15289
45366
32665

16.7
7.1
12.5
37.1
26.7

83.0
90.0
94.8
98.8
92.4

(82.4, 83.4)
(89.3, 90.6)
(94.4, 95.2)
(98.6, 98.8)
(92.1, 92.7)

71.8
82.0
88.0
96.4
88.8

(71.0, 72.4)
(81.0, 82.9)
(87.4, 88.7)
(96.1, 96.5)
(88.4, 89.2)

3571
10754
16299
21238
7840
62689
122391

2.9
8.8
13.3
17.4
6.4
51.2
100.0

99.4
99.2
98.8
96.0
90.6
90.0
93.4

(99.0, 99.7)
(98.9, 99.3)
(98.5, 98.9)
(95.8, 96.4)
(89.8, 91.1)
(89.7, 90.2)
(93.2, 93.4)

97.8
97.2
96.4
90.8
82.4
83.8
88.2

(97.1, 98.5)
(96.7, 97.6)
(96.0, 96.8)
(90.3, 91.2)
(81.3, 83.3)
(83.4, 84.1)
(87.9, 88.3)

CR1: 1-year cumulative relative survival proportion.
CICR1: 95% confidence interval of 1 –year cumulative survival rate.
CR3: 3-year cumulative relative survival proportion.
CICR3: 95% confidence interval of 3 –year cumulative survival rate.
MSM: men who have sex with men.
MSM+IDU: men who have sex with men and injection drug user;
HC: heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;
AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus.
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.
Viraload: HIV RNA copy number.
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Tables 3 Relative excess hazard rate of death within 3 years among
patients with HIV or AIDS diagnosed from 1996 to 2003
AIDS
Characteristics
Race/ethnicity
non-Hispanic white
non-Hispanic black
Hispanic
Asian/Pacific Islander
American Indian/Alaska Native
Age at diagnosis (years)
13-19
20-29
30-39
40-49
50-59
60+
Transmission category
MSM
IDU Male
IDU Female
MSM+IDU
HC Male
HC Female
Unknown
Sex
Male
Female
Diagnosis year
1996
1997

RR**

patients
AIDS RR 95% CI

HIV infection patients*
RR**

HIV RR 95% CI

1.00
1.15
1.18
0.95
1.41

(1.13, 1.17)
(1.15, 1.21)
(0.86, 1.04)
(1.26, 1.59)

1.00
1.02
1.07
0.91
1.37

(0.98, 1.07)
(1.00, 1.15)
(0.69, 1.21)
(1.12, 1.67)

1.00
2.00
2.43
3.26
4.53
6.93

(1.71, 2.33)
(2.09, 2.83)
(2.80, 3.80)
(3.89, 5.28)
(5.94, 8.09)

1.00
2.55
4.81
7.19
11.17
20.14

(1.83, 3.55)
(3.47, 6.68)
(5.19, 9.98)
(8.04, 15.5)
(14.5, 28.1)

1.00
1.51
1.65
1.08
1.01
1.15
1.54

(1.48, 1.55)
(1.58, 1.74)
(1.04, 1.13)
(0.98, 1.05)
(1.10, 1.20)
(1.50, 1.58)

1.00
1.55
1.73
1.14
0.83
0.97
1.37

(1.46, 1.65)
(1.55, 1.94)
(1.02, 1.27)
(0.76, 0.90)
(0.88, 1.07)
(1.30, 1.44)

1.00
0.98

(0.95, 1.02)

1.00
0.92

(0.86, 0.98)

1.00
0.86

(0.84, 0.89)

1.00
0.89

(0.83, 0.95)
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1998
1999
2000
2001
2002
2003
First CD4 CNT
<50
50-99
100-199
>=200
Unknown
Log10(viraload)
1-2
3
4
5
6-8
Unknown

0.86
0.84
0.86
0.83
0.77
0.69

(0.84, 0.88)
(0.81, 0.86)
(0.83, 0.88)
(0.81, 0.86)
(0.75, 0.80)
(0.66, 0.71)

0.87
0.84
0.79
0.82
0.69
0.66

(0.82, 0.93)
(0.78, 0.90)
(0.74, 0.85)
(0.76, 0.88)
(0.64, 0.74)
(0.61, 0.71)

1.00
0.64
0.38
0.40
0.92

(0.62, 0.65)
(0.38, 0.39)
(0.39, 0.41)
(0.90, 0.94)

1.00
0.57
0.36
0.13
0.35

(0.54, 0.61)
(0.34, 0.39)
(0.12, 0.14)
(0.34, 0.37)

1.00
2.24
3.83
6.01
8.49
13.87

(1.92, 2.62)
(3.31, 4.44)
(5.21, 6.93)
(7.35, 9.80)
(12.1, 16.0)

1.00
1.79
2.80
5.11
7.84
10.49

(1.20, 2.69)
(1.90, 4.12)
(3.51, 7.43)
(5.39, 11.4)
(7.24, 15.2)

*HIV infection diagnosed with or without a concurrent diagnosis of AIDS
**Relative excess hazard rate adjusted for all other variables (follow up period result not shown)
MSM: men who have sex with men; IDU: injection drug user;
MSMIDU: men who have sex with men and IDU: injection drug user;
HC: heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;
AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus.
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.
Viraload: HIV RNA copy number.
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Table 4 AIDS free survival proportion from HIV to AIDS diagnosed
from 1996 to 2003, by 25 US States

Characteristics
Race/ethnicity
Non-Hispanic white
Non-Hispanic black
Hispanic
Asian/Pacific Islander
American Indian/Alaska Native
Age at diagnosis (years)
13-19
20-29
30-39
40-49
50-59
60+
Transmission category
MSM
IDU Male
IDU Female
MSM IDU
HC Male
HC Female
Unknown
Sex
Male
Female
HIV diagnosis year
1996
1997

Frequency

Percent

P1

CIP1

P3

CIP3

42120
68373
10360
636
890

34.4
55.9
8.5
0.5
0.7

58.3
62.6
55.0
58.3
60.9

(57.8, 58.7)
(62.3, 63.0)
(54.0, 56.0)
(54.4, 62.1)
(57.6, 64.0)

51.6
53.29
47.5
51.8
51.6

(51.1, 52.1)
(52.9, 53.7)
(46.5, 48.5)
(47.6, 55.9)
(48.0, 55.1)

3822
27822
46397
31023
9947
3368

3.1
22.7
37.9
25.4
8.1
2.8

86.7
75.6
59.2
52.3
46.2
39.2

(85.5, 87.7)
(75.1, 76.1)
(58.8, 59.7)
(51.8, 52.9)
(45.2, 47.1)
(37.6, 40.9)

77.0
66.8
51.0
44.2
39.1
33.9

(75.4, 78.5)
(66.1, 67.4)
(50.4, 51.4)
(43.6, 44.8)
(38.1, 40.2)
(32.2, 35.6)

43744
10856
5273
4245
20971
12222
25068

35.7
8.9
4.3
3.47
17.1
10.0
20.5

57.7
52.4
65.9
60.9
59.0
68.3
64.9

(57.2, 58.1)
(51.5, 53.3)
(64.6, 67.2)
(59.4, 62.3)
(58.3, 59.7)
(67.4, 69.1)
(64.3, 65.4)

49.8
42.8
55.0
50.0
52.3
61.1
55.8

(49.3, 50.3)
(41.8, 43.8)
(53.4, 56.4)
(48.2, 51.5)
(51.6, 53.0)
(60.2, 62.0)
(55.1, 56.5)

88572
33807

72.4
27.6

57.5
68.2

(57.2, 57.8)
(67.7, 68.6)

49.4
59.6

(49.0, 49.7)
(59.0, 60.2)

17708
16564

14.5
13.5

58.7
59.8

(57.9, 59.4)
(59.1, 60.5)

50.0
51.6

(49.2, 50.8)
(50.8, 52.5)
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1998
1999
2000
2001
2002
2003
Log10(viraload)
1-2
3
4
5
6-8
Unknown
Total

15227
14324
14923
14545
14862
14226

12.4
11.7
12.2
11.9
12.1
11.6

59.7
60.6
60.6
61.7
61.7
61.3

(58.9, 60.5)
(59.8, 61.4)
(59.8, 61.3)
(60.9, 62.5)
(60.9, 62.4)
(60.4, 62.0)

51.6
52.2
51.7
52.3
53.1
55.9

(50.8, 52.5)
(51.3, 53.1)
(50.8, 52.5)
(51.4, 53.2)
(52.2, 54.0)
(55.0, 56.7)

3570
10750
16297
21232
7841
62689
122379

2.9
8.8
13.3
17.4
6.4
51.23
100

60.5
69.2
72.5
51.2
29.5
62.8
60.4

(58.9, 62.1)
(68.4, 70.1)
(71.8, 73.2)
(50.5, 51.9)
(28.5, 30.5)
(62.4, 63.2)
(60.2, 60.7)

53.3
61.6
62.2
38.5
19.1
56.8
52.2

(51.6, 55.1)
(60.6, 62.6)
(61.3, 63.0)
(37.8, 39.2)
(18.2, 20.1)
(56.4, 57.2)
(51.9, 52.5)

P1:
Percentage of 1 year AIDS free survival proportion after HIV diagnosis.
CIP1: 95% confidence interval of P1.
P3:
Percentage of 3 year AIDS free survival proportion after HIV diagnosis.
CIP3: 95% confidence interval of P3.
MSM: men who have sex with men.
HC: heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;
MSM+IDU: men who have sex with men and injection drug user.
AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus.
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.
Viraload: HIV RNA copy number.
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Table 5. Model comparison ( Estimated excess hazard ratio)

Model1
Time
Grouped
Distribution
Bin.*
Df.*
7.60E+04
Deviance
56179.50
Value/Df*.
0.74
Parameter
RER low_rer
Sex
Male
1.0
Female
0.99
0.95
Age at diagnosis
13-19
1.0
20-29
1.95
1.67
30-39
2.36
2.03
40-49
3.14
2.70
50-59
4.27
3.67
60+
6.27
5.37
Race/ethnicity
white
1.0
Black
1.16
1.13
Hispanic
1.16
1.13
Asian
0.94
0.86
Indian
1.41
1.26
Transmission category
MSM
1.0
IDU Male
1.50
1.46
IDU Female
1.63
1.56
MSM+IDU
1.10
1.05
HC Male
1.01
0.98
HC Female
1.14
1.09

hi_rer

Model2
grouped
Poi.*
7.60E+04
54500
0.719
rer
low_rer

hi_rer

Model3
exacted
Poi.*, Individual
9.10E+05
4.84E+05
5.30E-01
Rer low_rer

hi_rer

Model4
Exacted
Poi.*, collapsed
7.60E+04
5.91E+04
7.80E-01
rer
low_rer

hi_rer

1.03

0.99

0.96

1.03

0.98

0.95

1.02

0.98

0.95

1.02

2.28
2.75
3.65
4.98
7.31

1.96
2.37
3.15
4.24
6.00

1.68
2.04
2.70
3.63
5.14

2.29
2.77
3.67
4.95
7.02

1.86
2.27
3.04
4.22
6.42

1.59
1.94
2.60
3.60
5.48

2.19
2.65
3.56
4.94
7.53

2.00
2.43
3.26
4.53
6.93

1.71
2.09
2.80
3.89
5.94

2.33
2.83
3.80
5.28
8.09

1.18
1.19
1.03
1.58

1.15
1.16
0.94
1.37

1.13
1.13
0.86
1.22

1.17
1.18
1.03
1.55

1.15
1.18
0.95
1.42

1.13
1.15
0.87
1.26

1.18
1.21
1.04
1.59

1.15
1.18
0.95
1.41

1.13
1.15
0.86
1.26

1.17
1.21
1.04
1.59

1.54
1.71
1.14
1.05
1.19

1.50
1.62
1.09
1.01
1.14

1.46
1.55
1.05
0.98
1.08

1.53
1.70
1.13
1.05
1.19

1.51
1.65
1.08
1.01
1.15

1.48
1.57
1.04
0.97
1.09

1.55
1.73
1.13
1.04
1.20

1.51
1.65
1.08
1.01
1.15

1.48
1.58
1.04
0.98
1.10

1.55
1.74
1.13
1.05
1.20
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Unknown
Diagnosis year
1996
1997
1998
1999
2000
2001
2002
2003
First CD4 CNT
<50
50-99
100-199
>=200
Unknown
Log10(viraload)
1-2
3
4
5
6-8
Unknown

1.49

1.45

1.53

1.48

1.44

1.52

1.54

1.50

1.58

1.54

1.5

1.58

1.0
0.87
0.86
0.84
0.86
0.83
0.78
0.64

0.84
0.84
0.81
0.83
0.81
0.75
0.62

0.89
0.89
0.86
0.88
0.86
0.80
0.66

0.87
0.86
0.84
0.86
0.83
0.78
0.64

0.85
0.84
0.82
0.84
0.81
0.76
0.62

0.89
0.89
0.86
0.89
0.86
0.80
0.67

0.86
0.86
0.84
0.86
0.83
0.77
0.69

0.84
0.83
0.81
0.83
0.81
0.75
0.66

0.89
0.88
0.86
0.88
0.86
0.80
0.71

0.86
0.86
0.84
0.86
0.83
0.77
0.69

0.84
0.84
0.81
0.83
0.81
0.75
0.66

0.89
0.88
0.86
0.88
0.86
0.80
0.71

0.65
0.40
0.42
0.90

0.64
0.39
0.41
0.88

0.67
0.41
0.43
0.92

0.65
0.40
0.42
0.90

0.64
0.39
0.40
0.88

0.67
0.41
0.43
0.92

0.64
0.38
0.40
0.92

0.62
0.37
0.39
0.90

0.65
0.39
0.41
0.94

0.64
0.38
0.40
0.92

0.62
0.38
0.39
0.90

0.65
0.39
0.41
0.94

2.16
3.61
5.57
7.78
12.34

1.86
3.14
4.87
6.79
10.82

2.50
4.15
6.36
8.90
14.07

2.29
3.88
6.05
8.44
13.45

1.96
3.34
5.24
7.29
11.66

2.69
4.51
7.00
9.76
15.50

2.28
3.90
6.13
8.66
14.16

1.95
3.36
5.30
7.48
12.28

2.67
4.53
7.08
10.02
16.33

2.24
3.83
6.01
8.49
13.87

1.92
3.31
5.21
7.35
12.10

2.62
4.44
6.93
9.80
16.00

1.0

1.0

* Bin.: Binomial; Poi.: Poisson; Df.: Degree of freedom.
RER: relative excess hazard ratio; low_rer: low limit of 95% confidence of RER; hi_rer: upper limit of 95% confidence interval.
HC: heterosexual contact with a person at high-risk for or a person with HIV infection or AIDS;
MSM+IDU: MSM and IDU;AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus.
First CD4 CNT: First CD4+ T cell count within 6 months of AIDS diagnosis.
Viraload: HIV RNA copy number.
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Figure-1. This maximum likelihood tree of HIV
based on full-length pol gene sequences analysis, Phylogenetic relationships of
HIV-1 groups M, N, and O with four different SIVcpz isolates.
(This picture was from the text book: “Fields Virology, Chapter 60” )
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Figure-2. Survival after AIDS Diagnosis by Race
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Figure-3. Survival after AIDS Diagnosis by Age Group (years)
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Figure-4. Survival after AIDS Diagnosis by Transmission Category
MSM = men who have sex with men; IDU = injection drug user.
MSM+IDU= men who have sex with men and injection drug user.
HC = heterosexual contact with a high-risk individual person with HIV infection or
AIDS;
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Figure-5. Survival after AIDS Diagnosis by Diagnosis Year
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Figure-6. Survival after AIDS Diagnosis by Sex
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Figure-7. Survival after AIDS Diagnosis by CD4+ T Cell Count
(Note: CD4 count was obtained within 6 months after AIDS diagnosis)
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Figure-8 Survival after AIDS Diagnosis by Viral Load
Note: The number is Log10 (Viral load); >50% observations had missing value for
viral load.
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APPENDICES
Appendix A

AIDS
CD4
CDC
CI
CMV
GLM
HAART
HARS
HC
HCF
HCM
HCV
HIV
IDU
IDUM
IDUF
MSM
MSM+IDU
RSR
RR
Viraload
RER

Abbreviation

acquired immune deficiency syndrome
CD4 molecular positive T lymphocyte
Centers for Disease Control and Prevention
Cnfidence interval
cytomegaloviruses
generalized linear model
highly active antiretroviral therapy
HIV/AIDS reporting system
high-risk heterosexual contact
female high-risk heterosexual contact
male high-risk heterosexual contact
hepatitis C virus
human immunodeficiency virus
injection drug user
male injection drug user
female injection drug user
men who have sex with men
men who have sex with men and inject drugs
relative survival rate
relative (excess) hazard ratio
HIV RNA copy number
Relative excess hazard ratio
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Appendix B

SAS and S-plus codes

1, SAS code: AIDS to death relative survival analysis ( for table1 )
Note: the main difference of SAS codes for table 2, 3, 5 is the dataset, so I omitted
the SAS codes for tables 3, 5
First, to get the AIDS patients dataset, then get the population and mortality dataset
and the laboratory dataset. Finally obtain the cohort dataset by merging the
following datasets :
• National AIDS patients,
• National population data
• National mortality data,
• Laboratory data of HARS
1.1 SAS codes to obtain the AIDS data
options nodate nonumber nocenter ps=65 ls=120;
%let
%let
%let
%let
%let

dsmth=JUN06;
/* data set month and year */
startyr=1996; /* beginning AIDS dx year */
enddxyr=2003;
/* ending AIDS dx year */
endfupyr=2005;
/* ending follow-up year */
maxfupyr=3;
/* maximum follow-up years */run;

title1 "AIDS dx from &startyr to & endyr, reported to CDC as of
&dsmth";
data aids; set hars.as_&dsmth(keep = rep_st stateno race sex
adxyrmo adthyrmo ageaids _amode new_race race_w race_b race_i
race_p race_a hisp);
if ageaids>=13;
dxyr=int(adxyrmo/100);
if &startyr<=dxyr<=&enddxyr;
dxmo=mod(adxyrmo,100);
/* remove cases with missing months of diagnosis */
if dxmo in (0,.) then delete;
dthyr=int(adthyrmo/100);
dthmo=mod(adthyrmo,100);
/* remove cases with missing months of death */
if (dthyr ne .) and ((dthmo in (.,0)) or (adthyrmo<adxyrmo)) then
delete;
if dthyr ne . and dthyr<=&endfupyr
then do; death='1'; survmo=(dthyr*12+dthmo)-(dxyr*12+dxmo); end;
else do; death='0'; survmo=(&endfupyr*12+12)-(dxyr*12+dxmo); end;
*****mapping new race back to old race***;
length old_race $1;
old_race=' ';
if new_race = '1' then old_race = '3';

54
else if new_race = '2' then old_race = '5';
else if new_race in ('3','5','7') then old_race = '4';
else if new_race = '4' then old_race = '2';
else if new_race = '6' then old_race = '1';
else if new_race = '8' then
do;
if (race_a = '1' and race_p = '1') and not (race_w = '1' or
race_b = '1' or race_i = '1' or race in('1', '2', '3', '5')) then
old_race = '4';
else old_race = '9';
end;
else old_race='9';
format old_race $SURRACE. ;
*******************************************************************
*******;
if old_race in('1','2','3','4','5');
if _amode = '01' then mode = '1';
/*reclassify risk group*/
else if _amode = '02' then mode = '2';
else if _amode = '03' then mode = '3';
else if _amode = '05' then mode = '5';
else mode='9';
if sex in('1','2');
keep rep_st stateno dxyr dxmo dthyr dthmo death survmo sex
old_race mode ageaids; run;
proc freq data=aids;
tables dxyr dxmo dthyr dthmo death survmo sex old_race mode
ageaids;
run;

1.2

SAS codes to obtain population and mortality data

/*get the mortality dataset*/
libname mort '\\cdc\project\DHAP_HICSB_Store1\NCHS MORTALITY
DATA\DthCertData\XUCyyyy'; run;
%macro mort(year=);
proc freq data=mort.Xuc&year;
tables year*sex*old_race*age/out=out&year missing noprint;
run;
%mend;
%mort(year=1996);
%mort(year=1997);
%mort(year=1998);
%mort(year=1999);
%mort(year=2000);
%mort(year=2001);
%mort(year=2002);
%mort(year=2003);
%mort(year=2004);
data mort; set out1996 out1997 out1998 out1999 out2000 out2001
out2002 out2003 out2004;
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death=count;
keep year sex old_race age death;

run;

/*get the population data */
%macro pop(range=,year=);
proc freq data=census.cty_&range;
tables sex*old_race*age/out=out&year missing noprint;
weight pop&year;
run;
%mend;
%pop(range=9099,year=96);
%pop(range=9099,year=97);
%pop(range=9099,year=98);
%pop(range=9099,year=99);
%pop(range=0005,year=00);
%pop(range=0005,year=01);
%pop(range=0005,year=02);
%pop(range=0005,year=03);
%pop(range=0005,year=04);
%pop(range=0005,year=05);
data pop; set out96(in=y96) out97(in=y97) out98(in=y98)
out99(in=y99) out00(in=y00)
out01(in=y01) out02(in=y02) out03(in=y03)
out04(in=y04) out05(in=y05);
pop=count;
if y96 then year='1996'; else
if y97 then year='1997'; else
if y98 then year='1998'; else
if y99 then year='1999'; else
if y00 then year='2000'; else
if y01 then year='2001'; else
if y02 then year='2002'; else
if y03 then year='2003'; else
if y04 then year='2004'; else
if y05 then year='2005';
keep year sex old_race age pop; run;
title 'National population by year, sex, old_race, and age';
proc freq data=pop;
tables year sex old_race age/missing;
weight pop; run;

Merge the population and mortality data
data mort2005; set mort;
if year='2004';
year='2005';
run;
data mort; set n.mort mort2005;
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if old_race='9' then delete;
if age>85 then age=85;
proc means noprint data=mort; by year sex old_race age;
var death;
output out=mort85 sum=death;
data prob; merge n.pop mort85; by year sex old_race age;
if age>=13;
_year=1*year;
_age=age;
prob=1-death/pop;
keep _year sex old_race _age prob; run;

After obtaining the AIDS, population , mortality , laboratory data, merging
them
/*get the aids dataset*/
data one ;
set a.aids ; by rep_st stateno ;
run;
proc contents data= one; run;
/*get the laboratory dataset */
data two ;
set HIV.lab2; by rep_st stateno;

run;

/*get the variables of first cd4 count year and month
*/
/*remove the cases if their first cd4 count was obtained 6 after
aids diagnosis */
data two1;
set two ; by rep_st stateno;
a= substr(th1yrmo, 1, 2);
b = substr(th1yrmo, 3, 2);
if a in ('.', '..') then delete ;
if b in ('.', '..') then delete ;
th1yr=int(th1yrmo/100);
th1mo=mod(th1yrmo,100);
if a= 0 then do _th1yr= 2000 + th1yr;
end; *year >= 2000;
else do
_th1yr= 1900+ th1yryr;
end; *year>=1996;
/* remove cases with missing months of first cd4 count test*/
if th1mo in (0,.) then cd4=.;
if 52=<th1yr<=95
then delete; *dxyr between 1952 and 1995;
*if th1yr=6 then delete ; run;

data cases ;
merge one (in = x ) two1; by
if x ; run;

rep_st

stateno;

/*if the first cd4 count was obtained 6 month after diagnosis,
take the first
cd4 count as missing */
data a.cases1;
set cases; by rep_st stateno;
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if ageaids>=13;
if th1yrmo<adxyrmo then cd4=.;
if _th1yr>= dxyr then do cd4mo =(_th1yr-dxyr)*12 + (th1mo-dxmo);
end;
if cd4mo>6 then do cd4 =.;
end ;
if th1yr in (.,
.. ) then do cd4 =. ;
end ;
if th1mo in ( .,
.. ) then do cd4 =. ;
end;
run;

*************************************************
/*reclassify the variables */
dataset for frequency table
**************************************************;
data a.cases2;
options nofmterr;
set a.cases1;
race =1*old_race;
agegrp=0;
if 13=<ageaids<=19 then agegrp= 1 ;
else if 20=<ageaids<=29 then agegrp=
else if 30=<ageaids<=39 then agegrp=
else if 40=<ageaids<=49 then agegrp=
else if 50=<ageaids<=59 then agegrp=
else if ageaids>=60 then agegrp= 6 ;
_cd4=0;
if
else if
else if
else if
else

0=<cd4 <50
50=<cd4 <=99
100=<cd4 <=199
cd4 >= 200

then
then
then
then

_cd4
_cd4
_cd4
_cd4
_cd4

=
=
=
=
=

2
3
4
5

;
;
;
;

1;
2;
3;
4;
5; *frist cd4 count missing;

_virload =0;
if
else if
else if
else if
else if
>6;
else
missing;

virload in (1
virload= 3
virload= 4
virload= 5
virload in (6

2)

7

8 )

then
then
then
then
then

_virload=
_virload
_virload
_virload
_virload

1;
= 2;
= 3;
= 4;
= 5; *virload

_virload

= 6; * virlaod

/*reclassify the mode value */
if mode = 5 then mode = 4; *amode = 5 ;
if mode =9 then mode=5;
*amode = 9;

if mode =1 then mode =1;
else if mode =2 and sex = 1
else if mode = 2 and sex =
else if mode = 3 then mode
else if mode = 5 and sex =

then mode = 2;
2 then mode = 3;
= 4;
1 then mode = 5;
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else if mode = 5 and sex = 2 then mode = 6;
else mode=7;
run;

/* There were 339863 observations read from the data set A.CASES1.
NOTE: The data set A.CASES2 has 339863 observations and 75
variables.
NOTE: DATA statement used (Total process time):*/
data a.aids1; set a.cases2; by rep_st stateno;
race= 1*old_race;
k=min(&maxfupyr,1+int((survmo-0.5)/12));
do fu=1 to k;
_year=dxyr+fu-1;
_age=ageaids+fu-1;
if _age>85 then _age=85;
if fu<k then do; y=1; d=0; w=0; end; else
if survmo>36 then do; y=1; d=0; w=1; end;
else do; y=max(0.5,survmo-(fu-1)*12)/12; d=1*death; w=1-d;
end;
output;
end;
keep rep_st stateno dxyr fu _year sex _cd4 _virload race _age
ageaids survmo mode y d w; run;

proc sort data=a.aids1; by _year sex race _age; run;

/*There were 913707 observations read from the data set A.AIDS1.
NOTE: The data set A.AIDS1 has 913707 observations and 16
variables.*/

/* import the dataset of population data set containing the
population mortality in a.popmort */

data a.aindivid;
merge a.aids1(in=f) a.popmort;
by _year sex race _age;
if f;
keep rep_st stateno _year sex race _cd4 _virload survmo _age
ageaids dxyr fu mode y d w prob; run;
proc sort data=a.aindivid; by rep_st stateno fu;

data a.aindivid1; set a.aindivid;
agegrp=0;
if 13=<_age<=19 then agegrp= 1 ;
else if 20=<_age<=29 then agegrp= 2 ;
else if 30=<_age<=39 then agegrp= 3 ;

run;
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else if 40=<_age<=49 then agegrp= 4 ;
else if 50=<_age<=59 then agegrp= 5 ;
else if _age>=60 then agegrp= 6 ;
length=1;
p_star=prob**length;
d_star=-log(p_star)*(y/length);
label
d_star='Expected number of deaths'
d='Indicator for death during interval'
w='Indicator for censored during interval'
y='Person-time (years) at risk during the interval'
length='Interval length (potential not actual)'
ln_y='ln(person-time at risk)'
p_star='Expected survival probability'
_age='Attained age'
_year='Attained calendar year'
range='Life table interval'
fu='Follow-up interval'
sex='Sex'
;
keep rep_st stateno _year sex race survmo _cd4 _virload
dxyr fu mode y d w
prob length p_star d_star; run;

agegrp

proc freq data =a.aindivid1;
tables _cd4
run;

sex race survmo

_virload mode

agegrp

dxyr fu d ;

/*add the variable byvar for computation the survival rate of total
group */
data a.atotal;
options nofmterr;
set a.aindivid1;
byvar=1; run;
proc contents data = a.aindivid1; run;
%macro summary (indata, outdata, var

) ;

proc summary data=&indata nway;
var d w p_star y d_star;
id length;
class &var fu; /* Follow-up must be the last variable in this list
*/
output out=&outdata (drop=_type_ rename=(_freq_=l))
sum(d w y d_star)=d w y d_star mean(p_star)=p_star; run;
%mend summary;
%summary(a.aindivid1, race1,
%summary(a.aindivid1, agegrp1,
%summary(a.aindivid1, mode1,

race
)
agegrp )
mode
)
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%summary(a.aindivid1,
%summary(a.aindivid1,
%summary(a.aindivid1,
%summary(a.aindivid1,
%summary(a.atotal,

sex1,
sex
)
dxyr1,
dxyr
)
_cd41,
_cd4
)
_virload1, _virload)
total1,
byvar
)

*******************************************************************
****************
/*computation and selection of 1, 3-year cumulative relative
survival probability*/
*******************************************************************
****************;

%macro surv(indata,outdata, var, num );
data outdata;
retain cp cp_star cr 1;
set &indata;
where fu<=3; * maximum follow up to 10 year, which can be changed
by requirement;
if fu=1 then do;
cp=1; cp_star=1; cr=1; se_temp=0;
end;
l_prime=l-w/2;
ns=l_prime-d;
/* Two alternative approaches to estimating interval-specific
survival */
/* Must use the hazard approach for period analysis */
p=exp(-(d/y)*length); /* transforming the hazard */
p=1-d/l_prime; /* actuarial approach */
r=p/p_star;
cp=cp*p;
cp_star=cp_star*p_star;
cr=cp/cp_star;
ln_y_group=log(l_prime-d/2);
ln_y=log(y);
d_star_group=l_prime*(1-p_star);
excess=(d-d_star)/y;
se_p=sqrt(p*(1-p)/l_prime);
se_r=se_p/p_star;
se_temp+d/(l_prime*(l_prime-d)); /* Component of the SE of the
cumulative survival */
se_cp=cp*sqrt(se_temp);
se_cr=se_cp/cp_star;
/* Calculate confidence intervals on the log-hazard scale and back
transform */
/* First for the interval-specific estimates */
if se_p ne 0 then do;
/* SE on the log-hazard scale using Taylor series approximation
*/
se_lh_p=sqrt( se_p**2/(p*log(p))**2 );
/* Confidence limits on the log-hazard scale */
lo_lh_p=log(-log(p))+1.96*se_lh_p;
hi_lh_p=log(-log(p))-1.96*se_lh_p;
/* Confidence limits on the survival scale (observed survival) */
lo_p=exp(-exp(lo_lh_p));
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hi_p=exp(-exp(hi_lh_p));
/* Confidence limits for the corresponding relative survival rate
*/
lo_r=lo_p/p_star;
hi_r=hi_p/p_star;
/* Drop temporary variables */
drop se_lh_p lo_lh_p hi_lh_p;
/* Formats and labels */
format lo_p hi_p lo_r hi_r 8.5;
label
lo_p='Lower 95% CI for P'
hi_p='Upper 95% CI for P'
lo_r='Lower 95% CI for R'
hi_r='Upper 95% CI for R'
;
end;
/* Now for the cumulative estimates */
if se_cp ne 0 then do;
/* SE on the log-hazard scale using Taylor series approximation
*/
se_lh_cp=sqrt( se_cp**2/(cp*log(cp))**2 );
/* Confidence limits on the log-hazard scale */
lo_lh_cp=log(-log(cp))+1.96*se_lh_cp;
hi_lh_cp=log(-log(cp))-1.96*se_lh_cp;
/* Confidence limits on the survival scale (observed survival) */
lo_cp=exp(-exp(lo_lh_cp));
hi_cp=exp(-exp(hi_lh_cp));
/* Confidence limits for the corresponding relative survival rate
*/
lo_cr=lo_cp/cp_star;
hi_cr=hi_cp/cp_star;
/* Drop temporary variables */
drop se_lh_cp lo_lh_cp hi_lh_cp;
/* Formats and labels */
format lo_cp hi_cp lo_cr hi_cr 8.5;
label
lo_cp='Lower 95% CI for CP'
hi_cp='Upper 95% CI for CP'
lo_cr='Lower 95% CI for CR'
hi_cr='Upper 95% CI for CR'
;
end;
drop se_temp;
label
/* range='Interval' */
fu='Interval'
l='Alive at start'
l_prime='Effective number at risk'
ns='Number surviving the interval'
d='Deaths'
w='Withdrawals'
p='Interval-specific observed survival'
cp='Cumulative observed survival'
r='Interval-specific relative survival'
cr='Cumulative relative survival'
p_star='Interval-specific expected survival'
cp_star='Cumulative expected survival'
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ln_y_group='ln(l_prime-d/2)'
ln_y='ln(person-time) (using exact times)'
y='Person-time at risk (using exact times)'
d_star='Expected deaths (using exact times)'
d_star_group='Expected deaths (approximate)'
excess='Empirical excess hazard'
se_p='Standard error of P'
se_r='Standard error of R'
se_cp='Standard error of CP'
se_cr='Standard error of CR'
;
format p cp r cr p_star cp_star 5.3;
run;
proc sort data = outdata; by &var

fu ; run;

data outdata;
retain r1 cr1 cr3 cr5 cr10 cr20 cir1 cicr1 cicr3 cicr5 cicr10 ;
length cicr5 $ 12;
set outdata;
by &var fu;
if fu=1 then do; r1=.; cr1=.; cr3=.; cr5=.; cr10=.; end;
if fu=1 then do; r1=r; cir1='('||put(lo_r,4.2)||',
'||left(put(hi_r,4.2))||')';
cr1=cr; cicr1='('||put(lo_cr,4.2)||',
'||left(put(hi_cr,4.2))||')'; end;
if fu=3 then do; r3=r; cir3='('||put(lo_r,4.2)||',
'||left(put(hi_r,4.2))||')';
cr3=cr; cicr3='('||put(lo_cr,4.2)||',
'||left(put(hi_cr,4.2))||')'; end;
*if fu=5 then do; *cr5=cr; *cicr5='('||put(lo_cr,4.2)||',
'||left(put(hi_cr,4.2))||')'; *end;
*if fu=10 then do; *cr10=cr; *cicr10='('||put(lo_cr,4.2)||',
'||left(put(hi_cr,4.2))||')'; *end;
*if fu=20 then do; *cr20=cr; *cicr20='('||put(lo_cr,4.2)||',
'||left(put(hi_cr,4.2))||')';* end;

keep

&var

r1 cir1 cr1 cicr1 r3 cir3 cr3 cicr3;

label
l_zero='l_zero'
r1 ='1-year RSR'
r3='3_year RSR'
cr1='1-year cum RSR'
cr3='3-year cum RSR';
*cr5='5-year cum RSR'
*cr10='10-year cum RSR';
*cr20='20-year cum RSR';
run;
data &outdata;
set outdata ;
do i = 1 to &num;
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m=3*i;
if _n_ = m then
end;

output;

keep
&var fu r1 cir1 cr1 cicr1 r3 cir3 cr3 cicr3;
%mend;
%surv(race1,
%surv(agegrp1,
%surv(mode1,
%surv(sex1,
%surv(dxyr1,
%surv(_cd41,
%surv( _virload1,
%surv(total1,

race2,
agegrp2 ,
mode2,
sex2,
dxyr2,
_cd42 ,
_virload2,
total2,

race,
agegrp,
mode,
sex,
dxyr,
_cd4,
_virload,
byvar,

5
6
7
2
8
5
6
1

run;

);
)
)
)
)
)
);
);

/*get the frequency for the aids relative survival table

*/

%Macro freq(indata, var1, var2, var3, var4, var5, var6, var7 );
%do i=1 %to 7;
ods output Freq.table&&i..OneWayFreqs=tab&&i;
%end;
proc freq data = &indata;
tables
race agegrp mode sex dxyr _cd4 _virload;
run;
%Mend freq;

%freq (a.cases2, race,

agegrp, mode, sex, dxyr

_cd4

_virload

%macro clean(indata, outdata, var );
data &outdata;
set &indata (keep = &var frequency percent );
run;
%mend clean ;
%clean(tab1, race3,
race )
%clean(tab2, agegrp3, agegrp )
%clean(tab3, mode3,
mode )
%clean(tab4, sex3,
sex )
%clean(tab5, dxyr3,
dxyr )
%clean(tab6, _cd43, _cd4)
%clean(tab7,_virload3, _virload )
/*merge the frequency table and the relative survival table
for each variables */
%macro merge(indata1, indata2, outdata, var
data &outdata ;
merge &indata1 &indata2; by &var;
run;
%mend;
%merge (
%merge (

race3,
agegrp3,

race2,
agegrp2,

);

race4,
agegrp4 ,

race
agegrp

)
)

)
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%merge
%merge
%merge
%merge
%merge

(
(
(
(
(

mode3,
sex3,
dxyr3,
_cd43,
_virload3,

mode2,
sex2,
dxyr2 ,
_cd42,
_virload2,

mode4,
sex4,
dxyr4,
_cd44,
_virload4,

mode
)
sex
)
dxyr
)
_cd4
)
_virload )

/*generate the survival table aids to death dataset */

The SAS code for table generation was omitted.
2. SAS code for table 2 (omitted is similar to the codes for Table1, the only
difference is table 2 use HIV to death data
3. SAS codes for relative excess hazard analysis (table3 )
1, To obtain the effects of AIDS (table 3 column 2,3 )
libname aids 'c:\xzhang18';
libname a 'c:\xzhang18\sasdata';
data individ;
options nofmterr;
set a.individ;
run;
data a.individ;
set individ;
ln_y=log(y);
run;
/****************************************************************
Collapse the data to produce the grouped .
****************************************************************/
proc summary data=a.individ nway;
var d w p_star y d_star;
id length;
class race agegrp sex _cd4 _virload mode dxyr fu;/*Follow-up must
be
the last variable in this list*/
output out=grouped (drop=_type_ rename=(_freq_=l))
sum(d w y d_star)=d w y d_star mean(p_star)=p_star;
run;
data a.grouped;

set grouped; run;

/****************************************************************
Calculate life table quantities.
****************************************************************/
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data a.grouped;
set a.grouped;
l_prime=l-w/2;
ns=l_prime-d;
/* Two alternative approaches to estimating interval-specific
survival */
/* Must use the hazard approach for period analysis */
p=exp(-(d/y)*length); /* transforming the hazard */
p=1-d/l_prime; /* actuarial approach */
ln_y_group=log(l_prime-d/2);
ln_y=log(y);
d_star_group=l_prime*(1-p_star);
excess=(d-d_star)/y;
label
fu='Interval'
l='Alive at start'
l_prime='Effective number at risk'
ns='Number surviving the interval'
d='Deaths'
w='Withdrawals'
p='Interval-specific observed survival'
p_star='Interval-specific expected survival'
ln_y_group='ln(l_prime-d/2)'
ln_y='ln(person-time) (using exact times)'
y='Person-time at risk (using exact times)'
d_star='Expected deaths (using exact times)'
d_star_group='Expected deaths (approximate)'
excess='Empirical excess hazard'
;
run;

data grouped2;
set a.grouped(obs= 20000) ;
run;

proc freq data = a.grouped ;
tables fu sex race _cd4 _virload mode agegrp dxyr ;

ods output parameterestimates=parmest
modelinfo=modelinfo
modelfit=modelfit
convergencestatus=converge
converged */
type3=type3estimates;

/*
/*
/*
/*

run;

parameter estimates */
Model information */
Model fit information */
Whether the model

/* Type III estimates */

66
proc genmod data=a.grouped ;
title 'Poisson error model fitted to collapsed data (based on exact
survival times) [model 4] ';
fwdlink link = log(_MEAN_-d_star);
invlink ilink= exp(_XBETA_)+d_star;
class sex agegrp race mode dxyr _cd4 _virload fu /param= ref
ref=first order= internal ;
model d = fu sex agegrp race mode dxyr _cd4 _virload
fu*sex fu*agegrp fu*race
fu*mode fu*dxyr fu*_cd4 fu*_virload
sex*agegrp sex*race sex*dxyr sex*_cd4 sex*_virload
agegrp*race agegrp*mode agegrp*dxyr agegrp*_cd4 agegrp*_virload
mode*dxyr mode*_cd4 mode*_virload
dxyr*_cd4 dxyr*_virload
_cd4*_virload /error=poisson offset=ln_y type3;
run;
ods output close;

data parmest;
set parmest;
if df gt 0 then do;
rer=exp(estimate);
low_rer=exp(estimate-1.96*stderr);
hi_rer=exp(estimate+1.96*stderr);
end;
run;

proc contents data =

parmest;

proc contents data= parmest;

run;

run;

data aidspar;
set parmest;
if parameter not in ( 'fu', 'intercept',
'scale') ;
aidsrer =rer;
cia='('||put(low_rer,4.2)||', '||left(put(hi_rer,4.2))||')';
keep parameter aidsrer CIa;
format aidsrer 4.2
;
run;

2, To obtain the effects of HIV (table 4 column 4,5 )

ibname aids 'c:\xzhang18';
libname a 'c:\xzhang18';
libname HIV 'G:\hivdata';
data Hindivid;
set HIV.Hindivid;
run;
proc contents data = hindivid;

run;
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proc freq data= hindivid;
tables
sex race _cd4 _virload mode dxyr agegrp;
run;
/****************************************************************
Collapse the data to produce the grouped .
****************************************************************/
proc summary data=Hindivid nway;
var d w p_star y d_star;
id length;
class race agegrp sex _cd4 _virload mode dxyr fu;/*Follow-up must
be
the last variable in this list*/
output out=grouped (drop=_type_ rename=(_freq_=l))
sum(d w y d_star)=d w y d_star mean(p_star)=p_star;
run;
data HIV.grouped;

set grouped; run;

/****************************************************************
Calculate life table quantities.
****************************************************************/
data grouped;
set HIV.grouped;
l_prime=l-w/2;
ns=l_prime-d;
/* Two alternative approaches to estimating interval-specific
survival */
/* Must use the hazard approach for period analysis */
p=exp(-(d/y)*length); /* transforming the hazard */
p=1-d/l_prime; /* actuarial approach */
ln_y_group=log(l_prime-d/2);
ln_y=log(y);
d_star_group=l_prime*(1-p_star);
excess=(d-d_star)/y;
label
fu='Interval'
l='Alive at start'
l_prime='Effective number at risk'
ns='Number surviving the interval'
d='Deaths'
w='Withdrawals'
p='Interval-specific observed survival'
p_star='Interval-specific expected survival'
ln_y_group='ln(l_prime-d/2)'
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ln_y='ln(person-time) (using exact times)'
y='Person-time at risk (using exact times)'
d_star='Expected deaths (using exact times)'
d_star_group='Expected deaths (approximate)'
excess='Empirical excess hazard'
;
run;
proc freq data = grouped ;
tables fu sex race _cd4 _virload mode agegrp dxyr ;

ods output parameterestimates=parmest
modelinfo=modelinfo
modelfit=modelfit
convergencestatus=converge
converged */
type3=type3estimates;

/*
/*
/*
/*

run;

parameter estimates */
Model information */
Model fit information */
Whether the model

/* Type III estimates */

proc genmod data=grouped ;
title 'Poisson error model fitted to collapsed data (based on exact
survival times) [model 4] ';
fwdlink link = log(_MEAN_-d_star);
invlink ilink= exp(_XBETA_)+d_star;
class sex agegrp race mode dxyr _cd4 _virload fu /param= ref
ref=first order= internal ;
model d = fu sex agegrp race mode dxyr _cd4 _virload
/
error=poisson offset=ln_y type3;
run;
ods output close;

/*
NOTE: Algorithm converged.
NOTE: The scale parameter was held fixed.
NOTE: The data set WORK.TYPE3ESTIMATES has 8 observations and 4
variables.
NOTE: The data set WORK.CONVERGE has 1 observations and 2 variables.
NOTE: The data set WORK.MODELFIT has 5 observations and 4 variables.
NOTE: The data set WORK.MODELINFO has 7 observations and 6
variables.
NOTE: The data set WORK.PARMEST has 36 observations and 9 variables.
NOTE: PROCEDURE GENMOD used (Total process time):
real time
3:52:16.44
cpu time
3:51:55.22
*/

data parmest;
set parmest;
if df gt 0 then do;
rer=exp(estimate);
low_rer=exp(estimate-1.96*stderr);
hi_rer=exp(estimate+1.96*stderr);
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end;
run;

proc contents data =

parmest;

proc contents data= parmest;

run;

run;

data HIV.HIVpar;
set parmest;
if parameter not in ( 'fu', 'intercept',
'scale') ;
HIVrer =rer;
ciHIV='('||put(low_rer,4.2)||', '||left(put(hi_rer,4.2))||')';
keep parameter HIVrer CIHIV;
format HIVrer 4.2
;
run;

data hiv.modelfit;
set modelfit; run;
data hiv.type3estimates;
set type3estimates; run;

4. SAS codes for Table 4(omitted ) , the SAS code difference between table1
and 4 is Table 4 use HIV to AIDS data

5. SAS codes for model comparison ( omitted )
6 S-plus codes for mean residual life ( from Dr. Qin )
# S code for EL based CI for MRL at xx
alpha<-0.05

# confidence level

# Please input xx, z and xdelta
xx<-12
# a time point at which the MRL needs to be
estimated
#x<-rexp(n=30, rate=1)
# liftime
#y<rexp(n=30, rate=0.2)
# censoring time
z<-h1[,3]
n<-length(z)
xdelta<-h1[,7]
ydelta<-1-xdelta
cenp<-mean(ydelta)

# vector of min(x,y), observed time

# censoring rate

xkm<-survfit(Surv(z, xdelta)~1, type="kaplan-meier")
xtable<-summary(xkm)
xt<-xtable$time
# distint death time from x sample
xtx<-xt[xt>=xx]
# distint death time greater than xx
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xtx1<-c(xt[xt<xx][length(xt[xt<xx])],xtx[-length(xtx)])
Fhat<-xtable$surv
# The K-M estimate for 1-F
Fhatx<-Fhat[xt>=xx]
Fhatx1<-c(Fhat[xt<xx][length(Fhat[xt<xx])],Fhatx[-length(Fhatx)])
dj<-xtable$n.event
# number of deaths at distint death time
djx<-dj[xt>=xx]
# number of deaths at death time greater than
xx
yj<-xtable$n.risk
yjx<-yj[xt>=xx]
cmu<-cumsum(Fhatx1*(xtx-xtx1))
meanmu<-cmu[length(cmu)]
# meanmu=sum(Fhatx1*(xtx-xtx1))
sigmax<-sum( ((meanmu-cmu)^2*djx/(yjx-djx))[yjx>djx] )/((Fhatx1[1])^2)
# variance of \wh M(xx)
Mhatxx<-meanmu/Fhatx1[1]
# Estimate for the MRL at xx, \wh
S(xx)=Fhatx1[1]

# Normal Approx. based CI for M(xx):
lowmx<-Mhatxx- qnorm(1-alpha/2)*(sigmax)^(1/2)
# lower limit of the normal approx. based CI
for M(x)
uppmx<-Mhatxx+ qnorm(1-alpha/2)*(sigmax)^(1/2)
# upper limit of the normal approx. based CI
for M(x)
widmx<-uppmx-lowmx
# length of normal approximation based CI for
M(xx)

sink("mrlexamp3eout")
cat("Sample size=", n, "level=",1-alpha, "xx=", xx, "Estimated Mxx=",
Mhatxx, "censoring rate=", cenp, "\n")
cat(" ","\n")
cat("lower limit of the normal approx. based CI for M(x) is:", lowmx, "\n")
cat("upper limit of the normal approx. based CI for M(x) is:", uppmx, "\n")
cat("length of the normal approx. CI for M(x) is:", widmx, "\n")
sink()
Mhatxx
Lowmx
uppmax

